Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Astrazeneca Plc (AZN)

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 131,072,168
  • Shares Outstanding, K 2,624,593
  • Annual Sales, $ 26,617 M
  • Annual Income, $ 3,196 M
  • 60-Month Beta 0.55
  • Price/Sales 4.88
  • Price/Cash Flow 15.43
  • Price/Book 8.31
Trade AZN with:

Options Overview

Details
  • Implied Volatility 24.01%
  • Historical Volatility 27.13%
  • IV Percentile 0%
  • IV Rank 0.60%
  • IV High 67.14% on 07/17/20
  • IV Low 23.75% on 03/26/21
  • Put/Call Vol Ratio 0.51
  • Today's Volume 11,251
  • Volume Avg (30-Day) 15,616
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 223,075
  • Open Int (30-Day) 253,204

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 0.62
  • Number of Estimates 3
  • High Estimate 0.73
  • Low Estimate 0.53
  • Prior Year 0.53
  • Growth Rate Est. (year over year) +16.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.88 +4.30%
on 03/12/21
51.21 -2.48%
on 03/22/21
+0.67 (+1.36%)
since 03/09/21
3-Month
46.48 +7.44%
on 03/04/21
54.65 -8.62%
on 01/26/21
-0.92 (-1.81%)
since 01/08/21
52-Week
45.39 +10.02%
on 04/13/20
64.94 -23.10%
on 07/20/20
+5.28 (+11.82%)
since 04/09/20

Most Recent Stories

More News
Pharma Stock Roundup: FDA Decision Delays for PFE, LLY, ABBV, AZN Vaccine Woes

FDA delays decision on Pfizer (PFE), AbbVie (ABBV) and Lilly's (LLY) filings for JAK inhibitor candidates. AstraZeneca's (AZN) COVID-19 vaccine troubles continue.

JNJ : 161.25 (-1.06%)
AZN : 49.94 (+0.89%)
PFE : 36.60 (+1.78%)
MRK : 76.31 (+1.09%)
LLY : 184.49 (+1.03%)
ABBV : 107.54 (+1.36%)
Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.

AZN : 49.94 (+0.89%)
PFE : 36.60 (+1.78%)
MRNA : 140.92 (+5.26%)
NVAX : 179.74 (+1.97%)
IBB : 148.73 (-0.44%)
XBI : 129.63 (-2.22%)
BBH : 176.92 (+0.43%)
FBT : 158.84 (-0.46%)
BTEC : 57.06 (-0.24%)
BNTX : 122.14 (+6.68%)
Novartis (NVS) Teams Up With Artios for Radioligand Therapies

Novartis (NVS) enters a three-year collaboration with Artios to strengthen its radiogland therapies pipeline.

AZN : 49.94 (+0.89%)
RHHBY : 41.9300 (+1.28%)
NVS : 87.55 (+0.64%)
BMY : 62.61 (+1.13%)
Gilead (GILD) Gets Full Approval for Breast Cancer Drug Trodelvy

Gilead (GILD) obtains full approval for its breast cancer drug, Trodelvy, in the United States for metastatic triple-negative breast cancer.

AZN : 49.94 (+0.89%)
RHHBY : 41.9300 (+1.28%)
GILD : 65.11 (+0.14%)
MRK : 76.31 (+1.09%)
Thinking about trading options or stock in ChargePoint Holdings, GameStop, Marathon Digital, AstraZeneca, or Nvidia?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHPT, GME, MARA, AZN, and NVDA.

AZN : 49.94 (+0.89%)
NVDA : 576.00 (+0.58%)
MARA : 49.00 (-1.65%)
CHPT : 27.65 (-3.25%)
GME : 158.36 (-6.99%)
AstraZeneca (AZN) COVID-19 Jab May Have Link to Rare Blood Clots

European regulators find a possible link between AstraZeneca's (AZN) COVID-19 vaccine and rare blood clot events.

AZN : 49.94 (+0.89%)
PFE : 36.60 (+1.78%)
MRNA : 140.92 (+5.26%)
BNTX : 122.14 (+6.68%)
AstraZeneca (AZN) COVID-19 Vaccine Dosing Halted in Kids Study

Oxford University pauses dosing in AstraZeneca's (AZN) COVID-19 vaccine study in children until U.K. regulator completes review of fresh rare blood clot events.

JNJ : 161.25 (-1.06%)
AZN : 49.94 (+0.89%)
PFE : 36.60 (+1.78%)
MRNA : 140.92 (+5.26%)
Depression Treatment Therapy Market 2021 | Size, Share, Growth, Trends, Analysis, Competitive Landscape, Revenue, Forecast Report 2021-2028

The global "depression treatment therapy market" size is expected to gain momentum backed by the increasing incidence of suicides and the growing number of psychiatrists that is likely to boost the adoption...

AZN : 49.94 (+0.89%)
LLY : 184.49 (+1.03%)
MRK : 76.31 (+1.09%)
NVS : 87.55 (+0.64%)
PFE : 36.60 (+1.78%)
AstraZeneca Announces Collaboration with Massachusetts General Hospital to Accelerate Digital Health Solutions

AstraZeneca has entered into a collaboration agreement with Massachusetts General Hospital (MGH), leveraging robust data and clinical best practices to create digital health solutions that address today's...

AZN : 49.94 (+0.89%)
Emergent (EBS) Gets Extra $23M for COVID-19 Vaccine Production

Emergent (EBS) receives additional $23 million from BARDA to support further expansion of manufacturing capacity for Johnson & Johnson's COVID-19 vaccine.

JNJ : 161.25 (-1.06%)
AZN : 49.94 (+0.89%)
GILD : 65.11 (+0.14%)
EBS : 77.35 (-1.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

3rd Resistance Point 50.65
2nd Resistance Point 50.41
1st Resistance Point 50.17
Last Price 49.94
1st Support Level 49.69
2nd Support Level 49.45
3rd Support Level 49.21

See More

52-Week High 64.94
Fibonacci 61.8% 57.47
Fibonacci 50% 55.17
Fibonacci 38.2% 52.86
Last Price 49.94
52-Week Low 45.39

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar